WS
ECYT

Wedbush Securities’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Wedbush Securities’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-10,600
Closed -$96K – 920
2018
Q1 		$96K Hold
10,600
– – 0.01% 756
2017
Q4 		$45K Buy
+10,600
New +$50.5K 0.01% 823
2017
Q2 		– Sell
-21,884
Closed -$56K – 892
2017
Q1 		$56K Sell
21,884
-3,400
-13% -$7.87K 0.01% 799
2016
Q4 		$64K Sell
25,284
-2,459
-9% -$7.06K 0.01% 769
2016
Q3 		$86K Sell
27,743
-2,595
-9% -$8.09K 0.01% 763
2016
Q2 		$97K Hold
30,338
– – 0.02% 698
2016
Q1 		$94K Hold
30,338
– – 0.02% 668
2015
Q4 		$122K Sell
30,338
-16,390
-35% -$75.5K 0.02% 633
2015
Q3 		$214K Sell
46,728
-3,382
-7% -$17.7K 0.04% 505
2015
Q2 		$260K Buy
50,110
+4,020
+9% +$24.1K 0.05% 474
2015
Q1 		$289K Sell
46,090
-4,950
-10% -$28.6K 0.05% 441
2014
Q4 		$321K Sell
51,040
-10,286
-17% -$62.7K 0.05% 384
2014
Q3 		$373K Buy
61,326
+20,790
+51% +$142K 0.06% 337
2014
Q2 		$267K Buy
40,536
+11,896
+42% +$134K 0.04% 436
2014
Q1 		$682K Buy
+28,640
New +$415K 0.12% 182

Other funds holding ECYT

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Wedbush Securities's ECYT Position: Q2 2018 in Review

Wedbush Securities sold out of Endocyte, Inc. Common Stock (ECYT) in Q2 2018, closing a stake of 10,600 shares — an estimated $96K sold.

Wedbush Securities first reported a position in ECYT in Q1 2014 and held it in 15 quarters. The position peaked at $682K in Q1 2014. 114 funds tracked by Wall St. Rank hold ECYT as of Q2 2018.

  • Wedbush Securities reported no remaining Endocyte, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • Wedbush Securities sold 10,600 Endocyte, Inc. Common Stock shares in Q2 2018, an estimated $96K.
  • Wedbush Securities first reported a position in Endocyte, Inc. Common Stock in Q1 2014 and held it in 15 quarters.
  • Wedbush Securities's Endocyte, Inc. Common Stock position peaked at $682K in Q1 2014.
  • 114 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q2 2018.

Based on Wedbush Securities's 13F filing for Q2 2018, filed 3 Aug 2018.